☆ 4.6 Review

Treatment Emergent Dolutegravir Resistance Mutations in Individuals Naive to HIV-1 Integrase Inhibitors: A Rapid Scoping Review

VIRUSES-BASEL (2023)

Related references

Note: Only part of the references are listed.

Editorial Material Medicine, General & Internal

Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults 2022 Recommendations of the International Antiviral Society-USA Panel

Rajesh T. Gandhi et al.

Summary: Based on new data, recommendations are provided to clinicians on the use of antiretroviral drugs for the treatment and prevention of HIV, as well as on laboratory monitoring, care of aging individuals with HIV, substance use disorder, and new challenges such as COVID-19 and monkeypox virus infection. The initiation of antiretroviral therapy as soon as possible after HIV diagnosis is recommended, along with addressing barriers to care and ensuring access to medication and adherence support. Advances in treatment and prevention of HIV have improved outcomes, but challenges and opportunities still exist.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2023)

Add to Collection

Article Infectious Diseases

Emerging integrase strand transfer inhibitor drug resistance mutations among children and adults on ART in Tanzania: findings from a national representative HIV drug resistance survey

Doreen Kamori et al.

Summary: Despite the scale-up of HIV treatment and the introduction of dolutegravir in Tanzania, viral load suppression has not been fully achieved, possibly due to acquired drug resistance mutations. This study aimed to determine the prevalence and patterns of drug resistance mutations among HIV patients in Tanzania.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2023)

Add to Collection

Article Infectious Diseases

Breaking the unbreakable: A paediatric case of dolutegravir resistance from KwaZulu-Natal

Sibongiseni Malinga et al.

Summary: We report a case of dolutegravir resistance in a 13-year-old male patient in KwaZulu-Natal, South Africa, two years after starting dolutegravir treatment. Poor adherence due to psychosocial issues is the most likely cause of resistance. This case highlights the importance of family support and close monitoring in treatment-experienced patients who switch to dolutegravir-based regimens and experience virologic failure.

SOUTHERN AFRICAN JOURNAL OF HIV MEDICINE (2023)

Add to Collection

Article Microbiology

The G118R plus R263K Combination of Integrase Mutations Associated with Dolutegravir-Based Treatment Failure Reduces HIV-1 Replicative Capacity and Integration

Meng A. Xiao et al.

Summary: This study found that the combination of G118R and R263K integrase mutations can result in high levels of drug resistance and may affect the virus's replicative capacity and infectivity. Moreover, this combination of mutations also increases the resistance of the virus to bictegravir, so it may not be effective after dolutegravir failure.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2023)

Add to Collection

Article Infectious Diseases

Dolutegravir-associated resistance mutations after first-line treatment failure in Brazil

Ricardo Sobhie Diaz et al.

Summary: Compared to previous reports, a relatively high frequency of integrase resistance-associated mutations (INRAMs) was found among patients failing first-line treatment with TL + D in the Brazilian public health system. Possible reasons for this discrepancy include delays in detecting virologic failure, patients inadvertently on dolutegravir monotherapy, transmitted resistance mutations (TDR), and/or infecting subtype.

BMC INFECTIOUS DISEASES (2023)

Add to Collection

Article Infectious Diseases

Three-year efficacy of switching to dolutegravir plus lamivudine: A real-world study

E. Palmier et al.

Summary: This retrospective study examined 358 treatment-experienced patients with HIV who were receiving Dolutegravir (DTG) plus lamivudine (3TC) therapy. At 144 weeks, HIV-RNA levels were below 50 copies/mL in 77.4% of patients in the intention-to-treat (ITT) analysis and in 95.5% of patients in the per-protocol (PP) analysis. A few patients developed mutations causing resistance to nucleosides and integrase. These findings confirm the long-term efficacy and tolerability of DTG+3TC in treatment-experienced individuals.

HIV MEDICINE (2023)

Add to Collection

Article Infectious Diseases

Evaluation of integrase resistance in individuals who failed a regimen containing dolutegravir in French and Italian clinical settings

Daniele Armenia et al.

Summary: This study aimed to evaluate integrase resistance and its predictors in HIV-1 infected individuals who failed a dolutegravir-based antiretroviral therapy. Major resistance mutations and genotypic susceptibility score were analyzed. The results showed that INSTI resistance was low and mainly related to previous first-generation INSTI exposure. Monitoring integrase resistance is crucial to preserve the efficacy of INSTI class in the future.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2023)

Add to Collection

Article Immunology

Efficacy and safety of three antiretroviral therapy regimens started in pregnancy up to 50 weeks post partum: a multicentre, open-label, randomised, controlled, phase 3 trial

Lameck Chinula et al.

Summary: This study compared the safety and virological efficacy of three commonly used antiretroviral therapy (ART) regimens for HIV-1 in pregnant women. The results showed that the ART regimen involving dolutegravir, emtricitabine, and tenofovir alafenamide had superior safety and virological efficacy compared to the regimen involving efavirenz, emtricitabine, and tenofovir disoproxil fumarate.

LANCET HIV (2023)

Add to Collection

Article Immunology

Real world use of dolutegravir two drug regimens

Conor Bowman et al.

Summary: Since 2015, DTG-2DR regimens have been used to treat 620 individuals, with a high success rate of viral suppression observed in the majority of patients. Only a small number of virological failures and side-effects were reported, with one patient developing resistance to integrase inhibitors. Overall, DTG-2DR demonstrates high efficacy in a real-world setting.

AIDS (2023)

Add to Collection

Article Infectious Diseases

Limited emergence of resistance to integrase strand transfer inhibitors (INSTIs) in ART-experienced participants failing dolutegravir-based antiretroviral therapy: a cross-sectional analysis of a Northeast Nigerian cohort

Adam Abdullahi et al.

Summary: This study investigated the resistance to dolutegravir-based ART in a cohort of HIV-infected individuals in North-East Nigeria, and found a low prevalence of resistance to dolutegravir, supporting its continued rollout and implementation in the region.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2023)

Add to Collection

Article Infectious Diseases

Factors Associated With Viral Suppression and Drug Resistance in Children and Adolescents Living With HIV in Care and Treatment Programs in Southern Tanzania

Samoel A. Khamadi et al.

Summary: This study investigated the prevalence of viral suppression and HIV drug resistance mutations among children and adolescents living with HIV in a specific region of Tanzania. The findings showed higher rates of viral suppression, but HIV drug resistance mutations were common in those without viral suppression.

JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY (2023)

Add to Collection

Article Microbiology

Emergence of Resistance in HIV-1 Integrase with Dolutegravir Treatment in a Pediatric Population from the IMPAACT P1093 Study

Cindy Vavro et al.

Summary: This study describes the mechanisms of emergent integrase strand transfer inhibitor (INSTI) resistance among adolescents and children receiving dolutegravir treatment and provides molecular and structural characterization to aid in the understanding of INSTI resistance mechanisms in antiretroviral-experienced populations.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2022)

Add to Collection

Article Microbiology

Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study

Mark Underwood et al.

Summary: In the phase IIIb DAWNING study, treatment-experienced adults who received dolutegravir showed emergence of treatment-emergent INSTI resistance-associated substitutions, with some participants developing mutations like G118R and R263K. These mutations were associated with a significant increase in dolutegravir resistance compared to baseline levels. Overall, the study highlights the complex pathway to dolutegravir resistance involving HIV-1 phenotypic changes and reduced viral fitness.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2022)

Add to Collection

Article Infectious Diseases

Specific mutations in the HIV-1 G-tract of the 3′-polypurine tract cause resistance to integrase strand transfer inhibitors

Atsuko Hachiya et al.

Summary: This study investigated the specific mutations in the G-tract of the 3'-PPT that confer resistance to integrase strand transfer inhibitors (INSTIs). The results showed that mutations at the second and fifth positions increased INSTI resistance, likely through a non-competitive mechanism of inhibition.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2022)

Add to Collection

Article Infectious Diseases

Integrase resistance emergence with dolutegravir/lamivudine with prior HIV-1 suppression

Boris Revollo et al.

Summary: This article reports a case of integrase resistance in a patient treated with co-formulated dolutegravir/lamivudine. It highlights the importance of carefully considering and monitoring drug-drug interactions, even when they are regarded as having a low potential.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2022)

Add to Collection

Article Immunology

Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial

Nicholas I. Paton et al.

Summary: The study compared the effectiveness of dolutegravir and darunavir, and determined which is more suitable for second-line therapy: maintaining tenofovir or switching to zidovudine. The results showed that dolutegravir is non-inferior to darunavir at 96 weeks, but has a higher risk of resistance. Tenofovir is superior to zidovudine in second-line therapy.

LANCET HIV (2022)

Add to Collection

Article Immunology

Dolutegravir Resistance in Malawi's National HIV Treatment Program

Joep J. van Oosterhout et al.

Summary: This article reviews the HIV drug resistance (HIVDR) data of Malawians on dolutegravir-based antiretroviral therapy and finds that 8 out of 27 samples sequenced successfully have dolutegravir HIVDR. The article emphasizes the urgent need to enhance HIVDR testing capacity in Malawi.

OPEN FORUM INFECTIOUS DISEASES (2022)

Add to Collection

Article Microbiology

Factors associated with HIV-1 resistance to integrase strand transfer inhibitors in Spain: Implications for dolutegravir-containing regimens

Horacio Gil et al.

Summary: This study analyzed the clinical, epidemiological, and virological features associated with INSTI resistance diagnosed in Spain. The results showed that INSTI resistance is uncommon and associated with long-term infections, older age, and additional resistance to other ARV drug classes. The study also found that INSTI resistance is rare in newly diagnosed HIV-1 infections.

FRONTIERS IN MICROBIOLOGY (2022)

Add to Collection

Article Infectious Diseases

HIV-1 resistance against dolutegravir fluctuates rapidly alongside erratic treatment adherence: a case report

Jeroen J. A. van Kampen et al.

Summary: This study reports a case of incomplete HIV-1 suppression and emergence of integrase resistance mutations in a patient on a dolutegravir-based regimen. Next-generation sequencing revealed the dynamics of resistance mutations and cumulative treatment adherence. Next-generation sequencing is recommended for clinical management of incomplete virological suppression.

JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE (2022)

Add to Collection

Article Virology

Mutations in the 3'-PPT Lead to HIV-1 Replication without Integration

Clemence Richetta et al.

Summary: This study discovered a drug-resistant virus to strand-transfer inhibitors with a mutation in the 3'-PPT region instead of the integrase gene. This mutation altered the reverse transcription process, leading to the accumulation of 1-LTR circular structures instead of linear DNA. The accumulation of 1-LTR circles enabled viral replication without integration of the viral genome.

JOURNAL OF VIROLOGY (2022)

Add to Collection

Article Immunology

Viral suppression and HIV-1 drug resistance 1 year after pragmatic transitioning to dolutegravir first-line therapy in Malawi: a prospective cohort study

Birgit Schramm et al.

Lancet HIV (2022)

Add to Collection

Letter Infectious Diseases

Low-level viraemia despite emergence of dolutegravir-resistant variants

Johannes C. Botha et al.

SOUTHERN AFRICAN JOURNAL OF HIV MEDICINE (2022)

Add to Collection

Article Pharmacology & Pharmacy

Genotypic correlates of resistance to the HIV-1 strand transfer integrase inhibitor cabotegravir

Soo-Yon Rhee et al.

Summary: This study reviewed the genetic mechanisms of resistance to Cabotegravir (CAB). The results showed that the most commonly selected mutations in patients developing virological failure while receiving CAB included Q148R, N155H, and E138K. The study also identified 14 drug resistance mutations significantly associated with reduced CAB susceptibility. The study highlights the importance of careful patient screening and close virological monitoring to prevent the emergence of drug resistance with the use of CAB.

ANTIVIRAL RESEARCH (2022)

Add to Collection

Article Microbiology

Mechanistic Analysis of the Broad Antiretroviral Resistance Conferred by HIV-1 Envelope Glycoprotein Mutations

Yuta Hikichi et al.

Summary: The presence of mutations in the HIV-1 envelope glycoprotein (Env) can lead to reduced susceptibility to multiple classes of antiretroviral drugs (ARVs) and may contribute to virological failure in patients. The accumulation of Env mutations in individuals failing integrase inhibitor therapy suggests a possible mechanism for drug resistance development without mutations in target genes. Understanding how Env mutations affect drug resistance may influence therapeutic strategies for ARV-treated patients.

MBIO (2021)

Add to Collection

Article Medicine, General & Internal

Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children

A. Turkova et al.

Summary: In this trial involving children and adolescents with HIV-1 infection who were starting first- or second-line treatment, dolutegravir-based ART was found to be superior to standard care.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Immunology

Characterization of Human Immunodeficiency Virus (HIV) Infection in Cisgender Men and Transgender Women Who Have Sex With Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083

Mark A. Marzinke et al.

Summary: The HPTN 083 trial demonstrated the effectiveness of CAB-LA in preventing HIV compared to TDF/FTC. While some infections were associated with low or unquantifiable drug concentrations, delayed HIV diagnosis led to delayed antiretroviral therapy and increased risk of drug resistance in some cases where participants received CAB despite undetected infection.

JOURNAL OF INFECTIOUS DISEASES (2021)

Add to Collection

Article Virology

HIV-1 Subtype C Drug Resistance Mutations in Heavily Treated Patients Failing Integrase Strand Transfer Inhibitor-Based Regimens in Botswana

Kaelo K. Seatla et al.

Summary: Limited real-world outcomes data on treatment-experienced HIV-1 C patients failing Integrase Strand Transfer Inhibitor-based regimens were studied. Resistance to DTG was more common in patients exposed to RAL cART, and individuals with 4-class drug resistance mutations plus integrase T97 and E157Q mutations had worse outcomes. Frequent viral load monitoring and genotypic resistance testing are necessary for HIV-1 C diagnosed individuals with treatment experience.

VIRUSES-BASEL (2021)

Add to Collection

Article Infectious Diseases

Dolutegravir in the long term in children and adolescents: frequent virological failure but rare acquired genotypic resistance

Pierre Frange et al.

Summary: While virological failure is relatively common in children/adolescents receiving dolutegravir, regimens combining dolutegravir with more than one fully active drug have a low rate of emergent drug resistance, supporting the recommendation of dolutegravir as part of preferred combinations in this population.

HIV MEDICINE (2021)

Add to Collection

Article Microbiology

Limited HIV-1 Subtype C nef 3′PPT Variation in Combination Antiretroviral Therapy Naive and Experienced People Living with HIV in Botswana

Kaelo K. Seatla et al.

Summary: This study found a high conservation of the HIV-1 nef gene 3'PPT motif in 'real-world' patients, with no differences observed based on VL suppression or INSTI-based cART failure. Future research should explore other HIV-1 regions for associations with DTG failure.

PATHOGENS (2021)

Add to Collection

Article Infectious Diseases

Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistance

Philip L. Tzou et al.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)

Add to Collection

Article Infectious Diseases

Susceptibility to HIV-1 integrase strand transfer inhibitors (INSTIs) in highly treatment-experienced patients who failed an INSTI-based regimen

Maria M. Santoro et al.

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2020)

Add to Collection

Article Infectious Diseases

Case report: Emergence of dolutegravir resistance in a patient on second-line antiretroviral therapy

Kairoonisha Mahomed et al.

SOUTHERN AFRICAN JOURNAL OF HIV MEDICINE (2020)

Add to Collection

Article Immunology

Long-Acting Injectable Cabotegravir plus Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials

Giuliano Rizzardini et al.

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2020)

Add to Collection

Article Medicine, General & Internal

Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study

Edgar T. Overton et al.

LANCET (2020)

Add to Collection

Article Infectious Diseases

Pan-resistant HIV-1 emergence in the era of integrase strand-transfer inhibitors: a case report

Maria C. Puertas et al.

LANCET MICROBE (2020)

Add to Collection

Article Multidisciplinary Sciences

Mutations in the HIV-1 envelope glycoprotein can broadly rescue blocks at multiple steps in the virus replication cycle

Rachel Van Duyne et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)

Add to Collection

Review Infectious Diseases

A systematic review of the genetic mechanisms of dolutegravir resistance

Soo-Yon Rhee et al.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)

Add to Collection

Article Infectious Diseases

Variability of the HIV-1 3′ polypurine tract (3′PPT) region and implication in integrase inhibitor resistance

Isabelle Malet et al.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)

Add to Collection

Article Virology

Antiviral activity of HIV-1 integrase strand-transfer inhibitors against mutants with integrase resistance-associated mutations and their frequency in treatment-naive individuals

Nicolas A. Margot et al.

JOURNAL OF MEDICAL VIROLOGY (2019)

Add to Collection

Letter Medicine, General & Internal

Failure of Dolutegravir First-Line ART with Selection of Virus Carrying R263K and G118R

Nadine Luebke et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Immunology

Dolutegravir Monotherapy Versus Dolutegravir/Abacavir/Lamivudine for Virologically Suppressed People Living With Chronic Human Immunodeficiency Virus Infection: The Randomized Noninferiority MONotherapy of TiviCAY Trial

Laurent Hocqueloux et al.

CLINICAL INFECTIOUS DISEASES (2019)

Add to Collection

Editorial Material Immunology

Development of the R263K Mutation to Dolutegravir in an HIV-1 Subtype D Virus Harboring 3 Class-Drug Resistance

N. Ahmed et al.

OPEN FORUM INFECTIOUS DISEASES (2019)

Add to Collection

Article Immunology

Virological Failure in HIV to Triple Therapy With Dolutegravir-Based Firstline Treatment: Rare but Possible

M. J. Pena et al.

OPEN FORUM INFECTIOUS DISEASES (2019)

Add to Collection

Article Immunology

Emergence of Integrase Resistance Mutations During Initial Therapy Containing Dolutegravir

Jennifer A. Fulcher et al.

CLINICAL INFECTIOUS DISEASES (2018)

Add to Collection

Article Infectious Diseases

Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial

Jose L. Blanco et al.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)

Add to Collection

Article Immunology

HIV-1 Resistance Dynamics in Patients With Virologic Failure to Dolutegravir Maintenance Monotherapy

Ingeborg E. A. Wijting et al.

JOURNAL OF INFECTIOUS DISEASES (2018)

Add to Collection

Letter Immunology

First reported case of integrase (R263K, G163R) and reverse transcriptase (M184V)-transmitted drug resistance from a drug-naive patient failing Triumeq

Sarah Cochrane et al.

AIDS (2018)

Add to Collection

Article Immunology

Rapid Development of High-Level Resistance to Dolutegravir With Emergence of T97A Mutation in 2 Treatment-Experienced Individuals With Baseline Partial Sensitivity to Dolutegravir

Jomy M. George et al.

OPEN FORUM INFECTIOUS DISEASES (2018)

Add to Collection

Letter Immunology

Two cases of dolutegravir failure with R263K mutation

Margarida Cardoso et al.

AIDS (2018)

Add to Collection

Article Immunology

ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)-infected Participants With HIV-1 RNA < 500 000 Copies/mL

Babafemi O. Taiwo et al.

CLINICAL INFECTIOUS DISEASES (2018)

Add to Collection

Article Infectious Diseases

Dolutegravir monotherapy as treatment de-escalation in HIV-infected adults with virological control: DoluMono cohort results

Celia Oldenbuettel et al.

ANTIVIRAL THERAPY (2017)

Add to Collection

Article Immunology

Current Status of Point-of-Care Testing for Human Immunodeficiency Virus Drug Resistance

Horacio A. Duarte et al.

JOURNAL OF INFECTIOUS DISEASES (2017)

Add to Collection

Article Microbiology

Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors

Isabelle Malet et al.

MBIO (2017)

Add to Collection

Article Immunology

Dolutegravir as maintenance monotherapy for HIV (DOMONO): a phase 2, randomised non-inferiority trial

Ingeborg Wijting et al.

LANCET HIV (2017)

Add to Collection

Article Immunology

Emergent drug resistance with integrase strand transfer inhibitor-based regimens

Katherine J. Lepik et al.

AIDS (2017)

Add to Collection

Article Immunology

Q148N, a Novel Integrase Inhibitor Resistance Mutation Associated with Low-Level Reduction in Elvitegravir Susceptibility

Vici Varghese et al.

AIDS RESEARCH AND HUMAN RETROVIRUSES (2016)

Add to Collection

Article Microbiology

Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile

Manuel Tsiang et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)

Add to Collection

Article Infectious Diseases

Polymorphic substitution E157Q in HIV-1 integrase increases R263K-mediated dolutegravir resistance and decreases DNA binding activity

Kaitlin Anstett et al.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)

Add to Collection

Article Immunology

The R263K substitution in HIV-1 subtype C is more deleterious for integrase enzymatic function and viral replication than in subtype B

Thibault Mesplede et al.

AIDS (2015)

Add to Collection

Article Virology

Dolutegravir Resistance Mutation R263K Cannot Coexist in Combination with Many Classical Integrase Inhibitor Resistance Substitutions

Kaitlin Anstett et al.

JOURNAL OF VIROLOGY (2015)

Add to Collection

Article Virology

Differential Effects of the G118R, H51Y, and E138K Resistance Substitutions in Different Subtypes of HIV Integrase

Peter K. Quashie et al.

JOURNAL OF VIROLOGY (2015)

Add to Collection

Article Immunology

Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study

Antonella Castagna et al.

JOURNAL OF INFECTIOUS DISEASES (2014)

Add to Collection

Article Microbiology

Impact of Primary Elvitegravir Resistance-Associated Mutations in HIV-1 Integrase on Drug Susceptibility and Viral Replication Fitness

Michael E. Abram et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)

Add to Collection

Article Immunology

Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study

Joseph J. Eron et al.

JOURNAL OF INFECTIOUS DISEASES (2013)

Add to Collection

Article Medicine, General & Internal

Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study

Pedro Cahn et al.

LANCET (2013)

Add to Collection

Article Virology

Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure

Thibault Mesplede et al.

RETROVIROLOGY (2013)

Add to Collection

Article Immunology

The Activity of the Integrase Inhibitor Dolutegravir Against HIV-1 Variants Isolated From Raltegravir-Treated Adults

Mark R. Underwood et al.

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2012)

Add to Collection

Article Immunology

Comparison of the precision and sensitivity of the antivirogram and PhenoSense HIV drug susceptibility assays

J Zhang et al.

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2005)

Add to Collection

Article Virology

Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in human immunodeficiency virus-infected adults

JD Barbour et al.

JOURNAL OF VIROLOGY (2002)

Add to Collection

Article Biochemistry & Molecular Biology

Selecting models of nucleotide substitution: An application to human immunodeficiency virus 1 (HIV-1)

D Posada et al.

MOLECULAR BIOLOGY AND EVOLUTION (2001)

Add to Collection

© Peeref 2019-2024. All rights reserved.